Analyst Research Report Snapshot

Title:

OXFORD BIOMEDICA - NO SURPRISES IN RESULTS

Price:

$10.00

Provider:

Edison Investment Research

Date:

12 Mar 2010

Pages:

6

Type:

AcrobatPDF

Companies referenced:

OXB.L

Available for Immediate Download
Summary:

Oxford BioMedica remains an attractive recovery play: its current market cap implies little value is attributed to TroVax and the upside potential in the stock. With a solid cash position of £25.3m, the company has a good chance of partnering ProSavin on attractive economic terms (and re-partnering TroVax) in 2010. The year should also bring clinical catalysts, including further ProSavin Phase I/II data and the initiation of new trials –Phase IIb for TroVax in prostate cancer, Phase I/IIa for two ocular assets.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.